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B cell lymphoproliferative diseases represent nat-
ural mutagenesis experiments that shed light on 
normal B cell regulatory mechanisms (Rui et al., 
2011) in addition to being major causes of 
human morbidity and mortality. These take nu-
merous forms, encompassing non-Hodgkin and 
Hodgkin lymphomas, chronic lymphocytic leu-
kemia, Waldenström’s macroglobulinemia, my-
eloma, and clinical or subclinical monoclonal 
gammopathies (Shaffer et al., 2002). Learning 
about normal B cell regulation from malignant 
B cells is confounded, however, by the accumu-
lation of 20 or more protein-altering somatic 
mutations in malignant B cell clones (Morin et al., 
2011; Pasqualucci et al., 2011; Puente et al., 
2011). The drive toward malignancy must begin 
with individual mutations, but aside from a few 
well-studied mutations like MYC and BCL2 
translocations (ar-Rushdi et al., 1983; Tsujimoto 
et al., 1985; Vaux et al., 1988), little is known 
about the consequences of recurring lymphoma 
mutations individually or combinatorially for the 
behavior of otherwise normal mature B cells.
MYD88 mutations have emerged as one of 
the most frequently recurring mutations in 
mature B cell lymphoproliferative disease. So-
matic missense mutations in MYD88 were dis-
covered by Ngo et al. (2011) in 39% of cases of 
a common form of non-Hodgkin’s lymphoma, 
activated B cell type diffuse large B cell lym-
phoma (ABC-DLBCL), with a single L265P 
substitution accounting for 75% of the muta-
tions. The L265P mutation occurs in almost 
100% of cases of Waldenström’s macroglobu-
linemia (Treon et al., 2012; Xu et al., 2013), at 
least 47% of cases of IgM monoclonal gam-
mopathy of undetermined significance (Xu et al., 
2013), 3–10% of cases of chronic lymphocytic 
leukemia (Puente et al., 2011; Wang et al., 2011), 
and 13% of splenic marginal zone lymphoma 
(Trøen et al., 2013). Other TIR domain muta-
tions, such as S219C, predominate in germinal 
center B cell type diffuse large B cell lymphoma 
(GCB-DLBCL; Ngo et al., 2011).
MYD88 is an important adaptor protein 
that bridges TLR and the IL-1 receptor to the 
activation of downstream IL receptor–activated 
kinases (IRAKs) and NF-B transcription factor 
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MYD88L265P has recently been discovered as an extraordinarily frequent somatic mutation 
in benign monoclonal IgM gammopathy, Waldenström’s macroglobulinemia, and diffuse 
large B cell lymphoma. In this study, we analyze the consequences for antigen-activated 
primary B cells of acquiring MYD88L265P. The mutation induced rapid B cell division in the 
absence of exogenous TLR ligands and was inhibited by Unc93b13d mutation and chloro-
quine or TLR9 deficiency, indicating continued dependence on upstream TLR9 activation. 
Proliferation and NF-B activation induced by MYD88L265P were nevertheless rapidly coun-
tered by the induction of TNFAIP3, an NF-B inhibitor frequently inactivated in 
MYD88L265P–bearing lymphomas, and extinguished by Bim-dependent apoptosis. 
MYD88L265P caused self-reactive B cells to accumulate in vivo only when apoptosis was 
opposed by Bcl2 overexpression. These results reveal checkpoints that fortify TLR responses 
against aberrant B cell proliferation in response to ubiquitous TLR and BCR self-ligands and 
suggest that tolerance failure requires the accumulation of multiple somatic mutations.
© 2014 Wang et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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NF-B, and is disrupted by a range of activating somatic muta-
tions in CARD11 frequently found in non-Hodgkin lym-
phoma (Lenz et al., 2008; Jeelall et al., 2012). It is conceivable 
that BCR tolerance mechanisms might also be disrupted by 
uncontrolled activity of nucleic acid sensing TLRs or gain-
of-function MYD88 mutations, potentially initiating a vicious 
cycle of cross-activation by self-sensing BCRs and TLRs, but 
this theoretical possibility has yet to be examined.
Here, we analyze the effect of MYD88 mutations on 
the behavior of normal antigen-activated B cells, including 
B cells bearing self-reactive BCRs, using a retroviral gene 
transfer system in mice. We show that MYD88L265P initially 
breaks tolerance to RNA- or DNA-sensing TLRs, resulting in 
Unc93b1 and TLR9-dependent B cell proliferation in the ab-
sence of foreign ligands for TLR9. However, activation of 
NF-B signaling and proliferation by MYD88L265P is rapidly 
terminated through inhibition of NF-B signaling by Tnfaip3 
and by Bcl2/Bim-regulated apoptosis. These results reveal a 
multilayered mechanism for B cell tolerance to self-ligands of 
nucleic acid–sensing TLRs, whose progressive disruption by 
mutations often found in human B cells cross-interferes with 
tolerance to self-ligands of the BCR.
RESULTS
MYD88L265P mutation drives B cell proliferation  
independent of foreign TLR ligand in vitro
To investigate the consequences of MYD88 mutations arising 
in mature, antigen-activated B cells that lack other lymphoma 
mutations, we used retroviral gene transfer to introduce 
normal or mutated mouse Myd88 alleles into activated B cells 
from mice that bear a transgenic BCR to a known antigen, 
hen egg lysozyme (HEL; Goodnow et al., 1988; Fig. 1 A). 
B cells were activated by antigen, and then stimulated by CD40; 
retrovirally transduced with mutant Myd88, WT Myd88, or 
EGFP-only control reporter vectors; washed; and placed back 
into tissue culture in the absence of mitogen stimulation to 
compare the fate of EGFP+ cells over time (Fig. 1, A and B). 
We initially tested the effects of six MYD88 TIR domain 
mutations (Ngo et al., 2011): L265P, S219C, S222R, M232T, 
S243N, and T294P (Fig. 1 A). Four of the six, L265P (Mut1), 
S219C (Mut2), M232T (Mut4), and S243N (Mut5), pro-
moted mitogen-independent B cell proliferation in culture 
that was not observed when wild-type MYD88 was ex-
pressed, whereas S222R (Mut3) and T294P (Mut6) showed 
no proliferation. The wild-type and mutant Myd88 proteins 
were expressed at comparable levels, demonstrating that pro-
liferation resulted from specific mutations and not simply 
from overexpression of the protein (Fig. 1, B–D). B cells trans-
duced with the MYD88L265P:EGFP vector spontaneously in-
creased their number in the first 3 d of culture to 4–5 times 
the starting culture number, despite the absence of antigen or 
anti-CD40 antibody (Fig. 1 B). In contrast, over the same pe-
riod the MYD88WT:EGFP and empty:EGFP vector-transduced 
B cells did not increase in number (Fig. 1 B). EGFP non-
transduced B cells served as an internal control and all de-
clined in number over the course of 3 d, indicating that 
activation (Akira and Takeda, 2004). MYD88 has two distinct 
domains, the Toll/IL-1R like domain (TIR), via which MYD88 
proteins homodimerize upon activation, and the death do-
main (DD), which recruits IRAKs to form the signaling 
complex (Akira and Takeda, 2004). Interestingly, all MYD88 
lymphoma mutations are found in the TIR domain and result 
in uncontrolled formation of the MYD88–IRAK signaling 
complex (Ngo et al., 2011). An ABC-DLBCL cell line with 
the MYD88L265P mutation showed hyperphosphorylation of 
IRAK1 and elevated NF-B activity, whereas shRNA studies 
established that the dysregulated MYD88 to NF-B signaling 
was necessary for the survival of this cell line (Ngo et al., 
2011). Similarly evidence for this mutation driving exagger-
ated NF-B activity has been obtained in malignant cells from 
Waldenström’s macroglobulinemia (Treon et al., 2012) and 
CLL (Wang et al., 2011). However, it remains unclear whether 
MYD88L265P mutation actively drives the proliferation of these 
malignant B cells or only maintains their survival, and the 
consequences of MYD88L265P mutation in the precursors of 
malignant B cells that do not carry numerous other somatic 
mutations are unknown.
Discrimination between chemical components of infect-
ing microbes and self-tissues is the central problem for normal 
B cell regulation. B cells express multiple TLRs, each serving 
as a sensor for infection by binding evolutionarily conserved 
molecules that differ between microbes and self (Akira and 
Takeda, 2004; Beutler, 2004). TLR3, TLR7, and TLR9 bind 
features of RNA or DNA that are enriched in microbial as 
opposed to mammalian nucleic acids, such as unmethylated 
CpG-rich DNA sequences or double-stranded RNA (Krieg, 
2002). Because these features are also present at lower abun-
dance in self-nucleic acids, the nucleic acid–sensing TLRs 
must use additional mechanisms to ensure they tolerate and 
do not trigger immune responses to self-nucleic acids. The 
mechanisms for TLR self-tolerance are nevertheless not well 
understood. One important mechanism is restriction of the 
activity of TLR3, TLR7, and TLR9 to acidified endosomes, 
where microbes are frequently trafficked by endocytosis after 
being captured by cell surface immunoglobulin (B cell anti-
gen receptors [BCRs]). Restriction is achieved by Unc93b1-
mediated TLR3, TLR7, and TLR9 trafficking to endosomes 
(Tabeta et al., 2006; Kim et al., 2008), and by requirement for 
proteolytic activation of the TLR ectodomain by endosomal 
proteases active only at low pH (Ewald et al., 2008). Because 
self-binding BCRs are negatively selected through processes 
of central and peripheral B cell deletion, editing, and anergy 
(Goodnow and Ohashi, 2013), these BCR tolerance mecha-
nisms assist self–nonself discrimination with nucleic acid–
sensing TLRs in B cells.
TLR tolerance to self-nucleic acids breaks down when 
BCR tolerance mechanisms fail, allowing BCRs to capture 
self-nucleic acids directly or indirectly and deliver them to 
acidified endosomes (Leadbetter et al., 2002). TLR and BCR 
signaling converges on NF-B activation through separate 
adapter proteins, MYD88 and CARD11, respectively. BCR 
tolerance involves an uncoupling of CARD11 signals to 
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Figure 1. MYD88 mutations promote mitogen-independent B cell proliferation in vitro but, paradoxically, shut down NF-B. (A) Experimen-
tal strategy for retrovirally introducing mutant MYD88 into activated mature splenic B cells. HEL-specific B cells from IgHEL-transgenic mice were acti-
vated by HEL antigen in vivo and polyclonal B cells from nontransgenic mice were activated by including anti-IgM during culture with anti-CD40. After 
transduction, the cells were washed and cultured without these mitogens (day 0) or transplanted into syngeneic mice. Table shows the corresponding 
human and mouse amino acid substitutions tested. (B) Activated HEL antigen-specific B cells transduced with the indicated vectors were placed into fresh 
triplicate cultures in the absence of antigen or CD40 stimuli for 5 d. Mean and SD of EGFP+ cells expressing each vector were compared with the starting 
amount on day 0 of the cultures. Data are representative of at least three independent experiments. (C) Mean and SD of EGFP+ B cells transduced with 
the indicated vectors after 3 d in triplicate cultures without antigen or CD40 stimulation, relative to the number at the start of the cultures (dashed line) 
are representative of at least three independent experiments. (D) EGFP+ cells expressing the indicated vectors were sorted on day 1 of culture without 
antigen or CD40 stimuli, and lysates analyzed by SDS-PAGE and Western blot for MYD88 protein and tubulin as loading control. Numbers show densito-
metric measurements of MYD88 in each sample, expressed as relative to cells expressing the MYD88WT vector. (E) Cell division measured by CTV dilution 
on days 1 and 3 of culture without antigen or CD40 stimulation, gated on MYD88L265P:EGFP (MUT1) or MYD88WT:EGFP-transduced (WT) B cells or in non-
dividing empty:EGFP vector transduced B cells (EV). Unlabeled cells are shown by the open gray histogram. Data are representative of at least three inde-
pendent experiments. (F) EGFP+ cells expressing the indicated vectors were sorted on day 1 of culture without antigen or CD40 stimuli, and lysates were 
analyzed by SDS-PAGE and Western blot for phosphorylation of the p65 subunit of NF-B, with the blot sequentially reprobed with antibodies to MYD88. 
Tubulin was used as a loading control. (G) Mean fluorescent intensity (MFI) of cell surface expression of proteins encoded by NF-B–inducible genes, 
measured in independent triplicate cultures (mean and SD) by flow cytometry on day 1 of culture without antigen or CD40 stimuli, gated on EGFP+ cells 
transduced with the indicated vectors. Statistical analysis by Student’s t test. ns, not significant; *, P < 0.05; **, P < 0.01. Data are representative of at least 
three independent experiments.
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To test the involvement of TNFAIP3, we first measured 
the mRNA level of TNFAIP3 in B cells transduced with 
MYD88L265P and found it was increased 300% compared with 
B cells transduced with empty:EGFP vector (Fig. 2 A). We then 
took advantage of a recently discovered ENU mutant mouse 
strain, lasvegas, with a partial loss of function Tnfaip3 mutation 
in the OTU domain that abolishes deubiquitinating activity 
(Tnfaip3lsv; unpublished data). When B cells with homozygous 
Tnfaip3lsv mutation were transduced with MYD88L265P and 
cultured without mitogens, the number of EGFP+ B cells con-
tinued to increase between days 3 and 5, in contrast to the 
rapid drop that occurred in WT B cells expressing MYD88L265P 
(Fig. 2, B and E). WT and Tnfaip3lsv mutant B cells had diluted 
the cell division tracking dye, CTV, to comparable levels on day 
3 but by day 5 the mutant B cells had greater dilution (Fig. 2 F). 
The increased division of mutant B cells between days 3 and 5 
corresponded to less than one additional division (Fig. 2 F), con-
sistent with less than a doubling of the numbers of mutant cells 
over this time (Fig. 2 E), and is insufficient to account for the 
large difference in numbers of mutant and wild-type B cells at 
day 5. The main effect of Tnfaip3 mutation in B cells expressing 
MYD88L265P appears to be a delayed induction of apoptosis.
EGFP+ WT or Tnfaip3lsv B cells expressing MYD88L265P 
or control vectors were sorted on day 1 of culture without 
mitogens, and cell lysates were analyzed by Western blotting 
for phosphorylation of NF-B p65. MYD88L265P decreased 
p65 phosphorylation in WT cells, as observed above, but this 
effect was negated in Tnfaip3lsv B cells (Fig. 2 C). Likewise, in 
WT B cells MYD88L265P decreased the expression of CD23, 
CD25, CD95 and CD86 on EGFP+ cells relative to EGFP 
internal control B cells, but this was abolished in Tnfaip3lsv  
B cells (Fig. 2 D). These results established that the rapid shut 
down of MYD88L265P-driven B cell proliferation and NF-B 
activity is partially Tnfaip3 dependent.
MYD88L265P-driven B cell proliferation is chloroquine 
sensitive and Unc93b1 and IRAK dependent
To test if normal B cell proliferation induced by MYD88L265P 
required upstream signaling by the RNA/DNA-sensing re-
ceptors TLR3, TLR7, and TLR9, as has been observed in 
malignant ABC-DLBCL cell lines (unpublished data), we re-
peated the retroviral transduction experiments in B cells where 
RNA/DNA-sensing TLRs were inhibited. Trafficking of these 
TLRs to endosomal compartments needed for active signal-
ing was blocked by transducing B cells homozygous for the 
Unc93b13d mutation (Tabeta et al., 2006; Kim et al., 2008). 
Endosomal acidification needed for proteolytic activation of 
the TLR7 and TLR9 ectodomains was inhibited by treating 
the B cells with chloroquine (Ewald et al., 2008), and TLR9 
was selectively eliminated by transducing B cells homozygous 
for a Tlr9-null mutation (Hemmi et al., 2000). These genetic 
(Fig. 3, A–F) or pharmacological (Fig. 3, C and D) inter-
ventions specifically inhibited proliferation of MYD88L265P:
EGFP-expressing B cells, but had no effect on proliferation 
of CARD11L232LI:EGFP-expressing B cells tested in parallel. 
Slow residual division nevertheless consistently occurred in 
proliferation induced by MYD88L265P was limited to the 
B cells that expressed the mutation and not the result of a se-
creted or cell–cell interaction factor (Fig. 1 B). However, the 
MYD88L265P-induced proliferation was short lived and the 
numbers of live EGFP+ B cells dropped sharply after day 3 in 
culture (Fig. 1 B).
Cell division was measured by labeling the transduced 
B cells with cell trace violet (CTV), a dye that is progressively 
diluted with each cell division. MYD88L265P:EGFP+ B cells 
diluted the CTV dye over the course of 3 d as a result of mul-
tiple cell divisions (Fig. 1 E). Most B cells expressing compa-
rable levels of WT MYD88wildtype:EGFP or empty:EGFP 
vector did not divide over this time course, although a subset 
of MYD88WT–transduced B cells expressing very high levels of 
EGFP did persist and divide (Fig. 1 E and not depicted). In 
contrast, the accumulating B cells with MYD88L265P expressed 
the bicistronic MYD88L265P:EGFP vector over a broad range 
that mirrored the starting distribution and the distribution in 
cells transduced with empty:EGFP.
We next looked at the downstream pathways that drove 
the proliferation of MYD88L265P B cells. Since MYD88 and 
CARD11 are adaptor proteins that connect TLRs and the 
B cell antigen receptor, respectively, to NF-B activation, we 
compared the effects of activated mutant MYD88 and CARD11 
alleles on NF-B activity in primary B cells, alongside a mutant 
IKBKB allele (K171E; Rossi et al., 2011) that directly activates 
NF-B (Mercurio et al., 1997). As described previously (Jeelall 
et al., 2012), B cells transduced with CARD11L232LI:EGFP 
vector displayed increased NF-B p65 phosphorylation 
(Fig. 1 F). CARD11L232LI or IKKK171E increased expression of 
CD25, CD95, and CD69, whereas the latter also induced CD23, 
each encoded by an NF-B–induced gene (Fig. 1 G). Paradox-
ically, MYD88L265P-transduced B cells had markedly dimin-
ished NF-B p65 phosphorylation and decreased CD25, CD95, 
and CD23 expression relative to control B cells transduced 
with empty vector (Fig. 1, F and G).
TNFAIP3 mediates MYD88L265P-induced  
shutdown of proliferation and NF-B activation
The aforementioned experiments showed that B cell dysregula-
tion caused by MYD88L265P differs from other NF-B–activating 
lymphoma mutations in multiple respects: MYD88L265P-induced 
cell division in vitro was rapidly self-limiting, and MYD88L265P 
triggered a decrease instead of induction of NF-B–activated 
genes encoding CD23, CD25, and CD95. These results, together 
with the frequent co-occurrence of MYD88 and TNFAIP3 mu-
tations in ABC-DLBCL (Ngo et al., 2011), raised the possibility 
that MYD88L265P might have an intrinsically self-limiting effect 
on B cells by inducing a negative feedback loop through induc-
tion of TNFAIP3 (also designated A20). TNFAIP3 mRNA and 
protein are rapidly induced by NF-B and form a critical nega-
tive feedback loop to diminish NF-B activity by adding K48-
linked ubiquitin chains, removing K63-linked ubiquitin chains, 
and inhibiting the addition of linear ubiquitin chains to key 
molecules in the NF-B signaling axis (Harhaj and Dixit, 
2012; Tokunaga et al., 2012; Verhelst et al., 2012).
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Figure 2. Tnfaip3 curtails the effects of MYD88L265P on B cells. (A) EGFP+ B cells expressing the indicated vectors were sorted from three indepen-
dent cultures on day 1, and mRNA from each cell was converted to cDNA and analyzed on microarrays. Shown are the mean and SD arbitrary units of 
Tnfaip3 mRNA and a constitutively expressed B cell transcript, Cd79a, from each sample. *, P < 0.05. (B) WT or Tnfaip3lsv homozygous mutant polyclonal  
B cells were transduced with the indicated vectors and cultured in triplicates in the absence of mitogenic stimuli for 5 d. The number of EGFP+ transduced 
B cells and EGFP nontransduced control B cells in each culture was compared with the starting number on day 0 (mean and SD). Data are representative 
of three independent experiments. (C) Western blot analysis of EGFP+ WT or Tnfaip3lsv polyclonal B cells expressing the indicated vectors, sorted on day 1 
of culture without mitogenic stimuli, measuring phosphorylated p65 NF-B. Tubulin was used as a loading control. (D) Relative expression of CD23, CD25, 
CD95, and CD86 on EGFP+ WT or Tnfaip3lsv polyclonal B cells expressing MYD88L265P or empty vector compared with nontransduced EGFP B cells in the 
same culture. Mean and SD for triplicate cultures per group. Statistical analysis by Student’s t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data are repre-
sentative of two independent experiments. (E) WT or Tnfaip3lsv homozygous HEL-specific B cells were activated by HEL in vivo and anti-CD40 in vitro, 
transduced with indicated vectors, and cultured in triplicates in the absence of mitogenic stimuli for 7 d, and the number of EGFP+ transduced B cells and 
EGFP nontransduced B cells in each culture compared with starting number on day 0 (mean and SD). Data are representative of two independent experi-
ments. (F) Division of HEL-specific B cells measured by CTV dilution on days 1, 3, and 5 of triplicate cultures in the absence of antigen or anti-CD40 stim-
uli. Cells were gated on WT or Tnfaip3lsv transduced with MYD88L265P or nondividing B cells transduced with empty:EGFP vector (gray histogram) showing 
the median and SD CTV intensity. Data are representative of two independent experiments.
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5, 7, 11 and 14 d after transplantation for the number of 
EGFP+ donor B cells in the spleen. Flow cytometry was used 
to identify donor B cells by their surface expression of B220 
and IgM, and to enumerate the percentage and absolute number 
that expressed EGFP before and after transplantation (Fig. 4, 
A and B). While similar percentages and numbers of EGFP+ 
cells expressing each vector were injected into the mice (Fig. 4, 
C and G), the percentage and total number of EGFP+ cells 
expressing MYD88L265P increased 8 to 12 fold by day 5 
after transplantation whereas no increase occurred in control 
B cells expressing MYD88WT (Fig. 4, D–H). The increase in 
MYD88L265P-transduced B cells was accompanied by exten-
sive dilution of CTV, demonstrating that the mutation in-
duced at least eight rounds of cell division in many of the 
EGFP+ B cells in vivo (Fig. 4, B and F). When later times after 
transplantation were analyzed, there only a slight additional 
increase or decrease in the numbers of MYD88L265P-expressing 
B cells (Fig. 4 I). Thus, MYD88L265P was sufficient to initiate 
spontaneous proliferation of mature B cells both in vitro and 
in vivo, although in both cases the aberrant clonal growth was 
rapidly self-limiting.
MYD88L265P cooperates with dysregulated  
Bcl2 or Bim deficiency
Bcl2 mRNA and protein are frequently elevated in malignant 
B cells and correlate with poor clinical outcome (Shen et al., 
2004; Iqbal et al., 2006). Because Bcl2 inhibits B cell apoptosis 
induced by the Bim, Bak, and Bax proteins (Cory, 1995), we 
Unc93b13d or Tlr9 mutant B cells bearing MYD88L265P, indi-
cating either weak activation by other Unc93b1-independent 
receptors or low-level, receptor-independent signaling by the 
MYD88 mutant protein. Thus, mutations in MYD88 induce 
transient B cell proliferation in the absence of normal B cell 
mitogens that nevertheless depends for the most part on an 
intact DNA-sensing TLR9 signaling apparatus.
We tested whether downstream IRAK activity was also 
required for proliferation by treating transduced B cells with 
an IRAK1/4 inhibitor, N-acyl 2-aminobenzimidazole (Powers 
et al., 2006). MYD88L265P transduced B cells incubated with 
5 µM IRAK1/4 inhibitor showed an 80% reduction in pro-
liferation (Fig. 3 G). This inhibitory effect was specific for 
B cells carrying mutant MYD88, as the IRAK inhibitor had 
little inhibitory effect on proliferation of B cells transduced 
with vectors encoding gain-of-function alleles of CARD11 
or IKK analyzed in parallel cultures (Fig. 3 G).
MYD88L265P induces T cell–independent  
B cell proliferation in vivo
To examine the consequences of MYD88L265P mutation for 
normal B cells in vivo, we tracked its effect on mature retro-
virally transduced B cells transplanted into Rag1/ recipient 
mice. After in vitro transduction with MYD88L265P:EGFP, 
MYD88WT:EGFP, or empty:EGFP vector, as above, the acti-
vated B cells were loaded with the cell division dye CTV and 
transplanted by intravenous injection into syngeneic Rag1/-
recipient mice (Fig. 4 A). Groups of recipients were analyzed 
Figure 3. Role of nucleotide-sensing TLRs 
and downstream IRAKs in MYD88L265P-
driven B cell proliferation. (A, C, E, and G) Mean 
and SD of EGFP+ polyclonal B cells on  
day 3 relative to the starting cell numbers  
in triplicate cultures transduced with  
activated MYD88:EGFP, CARD11:EGFP, IKK:
EGFP, or empty:EGFP vectors. Relative  
growth is compared in WT or Unc93b13d/3d 
(3D) mutant B cells (A); WT B cells cultured 
from day 0 with 0 or 25 µM chloroquine 
(Chloro; C); WT or Tlr9/ (KO) B cells (E); and 
WT B cells in the in the presence or absence 
of 5 µM IRAK1/4 inhibitor (G). Statistical analy-
sis by Student’s t test: ns, not significant;  
*, P < 0.05; **, P < 0.01. Data are representa-
tive of two independent experiments. (B, D, 
and F) Cell division after 1 or 3 d of culture 
measured by CTV dilution in MYD88L265P:EGFP+  
B cells, comparing WT (red histogram) or 
Unc93b13d/3d (filled pink) B cells (B); WT B cells 
in either 0 (red histogram) or 25 µM chloro-
quine (filled pink; D); or WT (red histogram) or 
Tlr9/ (filled pink) B cells (D). As a reference 
for nondividing viable B cells, parallel cultures 
were established of CTV-labeled Vav-Bcl2  
B cells transduced with empty:EGFP vector 
(gray shaded histogram). Data are representative 
of two independent experiments.
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EGFP or empty:EGFP vector, and cultured without mito-
genic stimuli to enumerate EGFP+ cells. The number of WT 
control B cells expressing MYD88L265P increased until day 3, 
and then declined sharply by day 5 as observed above, whereas 
the corresponding Vav-Bcl2 B cells increased to greater num-
bers on day 3 and continued to increase by day 5 (Fig. 5 B). 
Vav-Bcl2 B cells transduced with the empty:EGFP-only vec-
tor did not proliferate, but survived better in culture than cor-
responding WT cells, as expected, because of resistance to 
apoptosis (Fig. 5 B). To distinguish if the increased accumula-
tion of Vav-Bcl2 B cells expressing MYD88L265P was caused by 
enhanced cell division or better survival of the progeny, the 
transduced B cells were labeled with CTV. Despite much 
higher accumulation of Vav-Bcl2 than WT control B cells, 
there was no difference in the dilution of CTV within the 
tested the possibility that the short-lived proliferative burst 
induced by MYD88L265P was curtailed by activation of this 
apoptotic pathway. Myd88WT:EGFP-, Myd88L265P:EGFP-, or 
empty:EGFP-transduced B cells washed off CD40 were 
placed in culture for either 1 or 3 d and stained intracellularly 
for Bim protein levels. Compared with empty:EGFP vector, 
B cells transduced with Myd88L265P showed elevated Bim 
protein on day 1 and day 3 (Fig. 5 A). The increased Bim in 
MYD88L265P-transduced cells contrasts with our previous find-
ing that Bim is decreased in B cells expressing activated 
Card11 or Ikk ( Jeelall et al., 2012). To test whether Bcl2 over-
expression could overcome the effects of Bim, activated B cells 
were obtained from Vav-Bcl2 transgenic mice that constitutively 
express Bcl2 in hematopoietic cells (Egle et al., 2004) and from 
WT control mice. These were transduced with MYD88L265P:
Figure 4. MYD88L265P mutation promotes 
T cell–independent B cell proliferation  
in vivo. (A) Antigen plus CD40-activated HEL-
specific B cells were transduced with the indi-
cated vectors, labeled with CTV, and analyzed 
at the time of injection into Rag1/ mice for 
the percentage EGFP+ (top) and CTV intensity 
(bottom). (B) Flow cytometric analysis of the 
spleen of Rag1/ recipient mice 5 d after 
transplantation of antigen-activated B cells 
transduced with the indicator vectors. Plots 
show concatenated data from three recipients 
per treatment. The top row shows the mean 
percentage and SD of B220+IgM+ transferred 
B cells. The middle row, gated on B220+IgM+ 
cells, shows the mean percentage and SD 
EGFP+ cells and expression of CD19. The  
bottom row, gated on B220+IgM+EGFP+  
cells, displays dilution of CTV as a measure  
of cell division and the total number of 
B220+IgM+EGFP+ events in each concatenated 
dataset. Data are representative of at least 
three independent experiments. (C) Number of 
EGFP+ B cells transduced with the indicated 
vectors injected into each recipient Rag1/ 
mouse analyzed in B. (D) Number of EGFP+  
B cells in the spleen of each recipient mouse 5 d 
after transplantation. Results show pooled 
data from two independent experiments, each 
with n = 3 per group. Statistical analysis by 
Student’s t test: **, P < 0.01. (E) Percentage of 
EGFP+ cells among transferred B cells at time 
of injection (day 0) and 5 d later in indepen-
dent recipient animals (n = 3 per group) num-
bers depict mean and SD of day 5 (F–H). 
Independent experiment performed and ana-
lyzed as in B–D. Statistical analysis by Stu-
dent’s t test: **, P < 0.01. (I) Number of EGFP+ 
B cells expressing the indicated vectors in the 
spleen of recipient mice on days 5, 7, 11, and 
14 after injection. Statistical analysis by 
ANOVA: ***, P < 0.001.
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Figure 5. Bcl2- and Bim-regulated apoptosis limits MYD88L265P-induced accumulation of mature B cells. (A) Intracellular BIM mean fluores-
cent intensity (MFI) gated on EGFP+ HEL-specific B cells transduced with indicated vectors and cultured without anti-CD40 for 1 or 3 d. Statistical com-
parison of independent cultures with empty vector or MyD88L265P by Student’s t test: *, P < 0.05; **, P < 0.01. (B and C) Proliferation of polyclonal WT or 
Vav-Bcl2 transgenic B cells transduced with the indicated vectors, labeled with CTV, and then cultured without exogenous stimuli for 1, 3, or 5 d. Data are 
representative of two independent experiments. (B) Mean and SD of EGFP+ or EGFP B cells in triplicate cultures relative to day 0. (C) Dilution of CTV in 
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transduced with MYD88L265P:EGFP or EGFP-only empty 
vectors were transplanted into Rag1/ mice that express 
HEL in their circulation as a self-antigen (Fig. 6 A). When 
analyzed 13 d after transfer, EGFP+ B cells expressing 
MYD88L265P proliferated and persisted in the absence of anti-
gen in nontransgenic Rag1/ control mice as observed pre-
viously, but were eliminated in HEL-transgenic recipients 
(Fig. 6, A–C). The unimpeded deletion of MYD88L265P- 
expressing B cells contrasts with the protection from elimina-
tion and induction of plasma cell differentiation induced by 
CARD11 mutations under the same experimental conditions 
(Jeelall et al., 2012).
Whereas MYD88L265P alone was insufficient to block 
antigen-induced death, we next asked if it could do so in 
cooperation with dysregulated Bcl2, given the cooperation ob-
served above in the absence of antigenic stimulation and the 
capacity of dysregulated Bcl2 alone to delay elimination of ma-
ture self-reactive B cells (Cyster et al., 1994). HEL-specific 
B cells transduced with MYD88L265P or empty vector were 
transferred into Rag1/ HEL-transgenic mice as above, except 
that half of the mice received B cells from Vav-Bcl2-Tg donors 
(Fig. 6 D). WT B cells transduced with the empty:EGFP or 
MYD88L265P:EGFP vectors were eliminated by day 13, whereas 
small numbers of Vav-Bcl2-Tg cells carrying empty vector sur-
vived; however, their frequency did not increase relative to the 
percentage EGFP+ on day 0 (Fig. 6, D–G). However the com-
bination of MYD88L265P and Vav-Bcl2 resulted in 10 times 
more EGFP+ B cells accumulating in HEL-transgenic recipi-
ents compared with Vav-Bcl2 alone and 200 times more EGPF+ 
B cells than empty vector alone (Fig. 6, D–F). In contrast to 
CARD11 mutations (Jeelall et al., 2012), the combination of 
MYD88L265P and Vav-Bcl2 mutations remained insufficient to 
drive spontaneous differentiation of self-antigen–stimulated 
B cells into CD19low plasmablasts, as the majority of accumu-
lating EGFP+ B cells remained CD19high (Fig. 6 D). Thus 
MYD88L265P was insufficient to interfere with BCR-in-
duced deletion on its own, but exhibited a highly cooperative 
interaction with dysregulated Bcl2 to block elimination of self-
reactive B cells and allow their accumulation.
DISCUSSION
B cells must normally tolerate self-ligands of their pathogen-
receptor systems (BCRs and TLRs) and only proliferate in 
response to foreign ligands for these receptors. The aforemen-
tioned experiments reveal that tolerance to nucleic acid-sensing 
TLRs is disrupted by a somatic mutation in MYD88 that is 
very frequently found in the benign disorder, IgM monoclonal 
MYD88L265P:EGFP+ population on days 3 or 5 (Fig. 5 C). 
Thus, the Vav-Bcl2 transgene did not alter the rate of cell divi-
sion induced by MYD88L265P but enhanced the accumulation 
of progeny at each division. Despite this, the modal CTV fluor-
escence only decreased from 1/8 to 1/16 of the nondividing 
empty-vector control cells between days 3 and 5 (Fig. 5 C), indi-
cating that MYD88L265P-induced B cell proliferation arrested 
after 4 divisions independent of apoptotic loss.
We then asked whether mutations that inhibit B cell apop-
tosis either through Bcl2 overexpression or inactivation of the 
proapoptotic Bim protein (Bcl2l11) also enhanced the accu-
mulation of MYD88L265P-expressing B cells in vivo, where the 
prosurvival cytokine BAFF/Blys is available (Woodland et al., 
2006). Transduced B cells from Vav-Bcl2 transgenic, Bim-
deficient (BimKO; Bouillet et al., 1999), or WT control mice 
were injected into Rag1/ recipient mice and spleen cells an-
alyzed 11 d after injection (Fig. 5 D). In control groups that re-
ceived B cells transduced with empty vector, three to four 
times more B220+IgM+ B cells remained in recipients that re-
ceived Vav-Bcl2 or BimKO B cells compared with WT B cells, 
which is consistent with enhanced survival of nontransduced 
and transduced B cells in vivo (Fig. 5 D). However the per-
centage of transferred B cells expressing the empty EGFP vec-
tor did not increase between the time of transfer and 11 d after 
transfer, regardless of Bcl2 or Bim genotype (black lines in 
Fig. 5 E). In contrast, the percentage of B cells expressing 
MYD88L265P:EGFP increased 4-fold by day 11 in the case of 
wild-type B cells, and increased 7-fold and 11-fold in Vav-Bcl2 
transgenic or Bim-deficient B cells, respectively (red lines in 
Fig. 5 E). Measured as total number of EGFP+ B cells, half 
as many EGFP+ cells were injected in the groups receiving 
Vav-Bcl2 or BimKO B cells (Fig. 5 D) due to lower transduced 
percentages on day 0 (Fig. 5 E). There was nevertheless a multi-
plicative effect of combining MYD88L265P with either Vav-Bcl2 
or BimKO on the numbers 11 d later: alone, each mutation 
increased the numbers of EGFP+ B cells by 6-fold relative to 
the number of empty-vector–expressing WT B cell controls, 
whereas combined they increased the number of EGFP+  
B cells 25–35-fold (Fig. 5, E and G).
MYD88L265P blocks self-antigen–induced elimination  
only when combined with dysregulated Bcl2
All lymphoma CARD11 mutations tested so far have the 
property of switching B cells from self-antigen–induced death 
into self-antigen–induced proliferation and plasma cell differ-
entiation (Jeelall et al., 2012). To test if lymphoma mutations 
in MYD88 have the same activity, HEL antigen–specific B cells 
EGFP+ cells transduced with MYD88L265P (red, WT cells; purple, Vav-Bcl2 cells) overlayed on the CTV fluorescence of the corresponding cells transduced 
with empty EGFP vector (gray histograms). (D–H) Polyclonal WT, Vav-Bcl2 transgenic, or Bcl2l11/ (BimKO) B cells were transduced with the indicated 
vectors and injected into Rag1/ recipient mice. (D) Representative flow cytometric analysis of spleen 11 d after transplantation. Percentage of cells in 
the indicated gates is shown. (E) Representative plots showing percentage of EGFP+ cells among transferred B cells at time of injection (day 0). Graphs on 
right compare the percentage on day 0 with day 11 in independent recipient animals, and numbers depict the mean fold increase and SD (n = 3 per 
group). (F) Total number of EGFP+ cells with the indicated vectors injected into each Rag1/ mouse. (G) Number of EGFP+ B cells in the spleen of indi-
vidual recipient mice 11 d after transplantation (n = 3). Statistical analysis by Student’s t test: *, P < 0.05.
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apoptosis. When the apoptotic checkpoint was corrupted by a 
second mutation, MYD88L265P promoted much greater B cell 
accumulation and blocked B cell elimination by self-antigen.
What drives the initial proliferation of MYD88L265P-
bearing primary B-cells? The inhibition of proliferation by 
the Unc93b13d mutation, chloroquine, and Tlr9 deficiency in-
dicates that activation of TLR9 is necessary, and hence the 
MYD88 mutation does not simply result in constitutively 
activated IRAK signaling. This result, in otherwise normal 
B cells, complements findings (unpublished data) that show 
malignant ABC-DLBCL cells bearing the MYD88L265P mu-
tation remain dependent on active TLR9 for their survival or 
proliferation. A linkage between dysregulated inflammatory 
gammopathy of undetermined significance, and in a range of 
B cell malignancies. In the absence of foreign TLR ligands, 
MYD88L265P was sufficient to drive multiple rounds of B cell 
division provided the Unc93b1-dependent and chloroquine-
sensitive steps in TLR9 activation were intact, and provided 
the B cells were not constantly binding self-antigen. This dis-
ruption of normal tolerance to TLR9 has parallels with the 
effects of weakly activating lymphoma CARD11 mutations, 
which break normal B cell tolerance to self-ligands of the BCR 
( Jeelall et al., 2012). However breakdown of TLR tolerance 
is fortified by more checkpoint mechanisms: MYD88L265P-
induced proliferation was rapidly curtailed by Tnfaip3-mediated 
shutdown of NF-B and by Bcl2-inhibited, Bim-dependent 
Figure 6. MYD88L265P blocks self-antigen induced B cell death only when combined with dysregulated Bcl2. (A) HEL-specific B cells were 
transduced with the indicated vectors and injected into Rag1/ mice or into Rag1/ HEL-transgenic mice. Transplanted B cells were defined and enu-
merated by their IgMa staining and HEL binding (top row), and the percentage of these B cells that expressed EGFP (bottom row). Data are representative 
of two independent experiments. (B) Number of EGFP+ B cells with the indicated vectors injected into each recipient mouse. (C) Number of EGFP+ B cells 
in the spleen of each recipient mouse 13 d after transplantation, results showing pooled data from two independent experiments, each with n = 3. Statis-
tical analysis by Student’s t test: **, P < 0.01. (D) As in A, except WT or Vav-Bcl2-Tg HEL-specific B-cells were transplanted into Rag1/ HEL-transgenic 
mice. Data are representative of two independent experiments. (E) Number of WT or Vav-Bcl2-Tg EGFP+ B cells injected into each recipient. (F) Number of 
EGFP+ B cells in the spleen of each recipient mouse 13 d after transplantation. Results showing pooled data from two independent experiments, each 
with n = 3. Statistical analysis by t test. *, P = 0.0019; **, P = 0.0024; ***, P = 0.0008. (G) Percentage of EGFP+ B cells among donor B cells on days 0 and 13. 
Statistical analysis by Student’s t test. *, P < 0.05.
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mechanisms to circumvent MYD88’s self-extinguishing prop-
erty. CARD11 mutations may evade this feedback mecha-
nism because CARD11 activates the paracaspase, MALT1, 
which cleaves and inactivates A20 (Coornaert et al., 2008; 
Rebeaud et al., 2008). MYD88 and CARD11 mutations also 
differed in their ability to counter cell death in the context of 
self-antigen stimulation, and this may reflect the capacity of 
activated CARD11 to diminish Bim protein levels ( Jeelall 
et al., 2012). In support of that interpretation, we found that 
deletion could only be blocked by MYD88L265P when com-
bined with a mutation that enforced expression of the Bim-
inhibitor, Bcl-2.
BCL2 t(14:18) translocations that cause dysregulated BCL2 
expression occur in almost half of apparently healthy adults and 
increase with age (Schüler et al., 2009). Many lymphomas bear-
ing MYD88L265P lack a BCL2 translocation. In these cases, per-
haps other recurring mutations provide alternative mechanisms 
to counteract Bim-induced apoptosis; e.g., by increasing BCL2 
expression from its normal locus. For example, the delayed 
apoptosis observed when MYD88L265P was combined with 
Tnfaip3 mutation may result from increased NF-B induc-
tion of Bcl2. The MYD88L265P and Vav-Bcl2 double mutation 
experiments indicate that additional layers of control exist 
to counter dysregulation of TLR responses even when 
MYD88L265P becomes paired with Bim inactivation via over-
expressed Bcl-2. Although the two mutations cooperate to pre-
vent elimination of self-reactive B cells, few of these rogue 
self-antigen–binding B cells differentiated into CD19low plas-
mablasts. This contrasts with lymphoma-associated CARD11 
mutations, where even the weakest alleles caused self-antigen 
to drive not only proliferation but also extensive differentia-
tion into plasmablasts (Jeelall et al., 2012).
Collectively, the findings in this study reveal checkpoints 
that normally prevent a single activating mutation in MYD88 
from triggering dysregulated B cell proliferation in response 
to self-protein, RNA, or DNA. These checkpoints provide 
insights into the clinical associations observed between MYD88 
somatic mutations and benign monoclonal IgM gammopathy 
(Xu et al., 2013); between somatic TNFAIP3 inactivation, 
MYD88 activation, and malignant DLBCL (Ngo et al., 2011); 
between inherited TNFAIP3 polymorphisms and rheuma-
toid arthritis or systemic lupus (Plenge et al., 2007; Thomson 
et al., 2007; Graham et al., 2008). They also provide insight 
into the association of these autoimmune diseases with devel-
opment of B cell lymphoma (Goodnow, 2007). Although self-
ligands for TLRs and BCRs are a ubiquitous potential stimulus 
for B cell proliferation and antibody secretion, the TLR sig-
naling pathway appears fortified to ensure this possibility 
can only arise through accumulation of multiple somatic or 
inherited mutations.
MATERIALS AND METhODS
Mice. Splenic mature B cells were obtained from (a) MD4 transgenic mice 
(Goodnow et al., 1988) bearing rearranged transgenic Ig encoding for HEL-
specific antibodies (IgHEL transgenic); (b) Vav-Bcl2 transgenic mice where Bcl2 
expression was driven by the pan-hematopoietic Vav1 promoter provided by 
responses and cancer has long been proposed, starting with 
Virchow back in 1863 (Balkwill and Mantovani, 2001). Since 
then, many studies have linked chronic infection and inflamma-
tion with B cell malignancy, most notably in gastric MALT lym-
phoma associated with Helicobacter pylori infection (Wotherspoon 
et al., 1993). The induction of proliferation and resistance to self-
antigen–induced elimination in B cells bearing the MYD88L265P 
mutation may represent an unbridled response to endogenous 
TLR9 ligands, with parallels to the B cell dysregulation observed 
in mice inheriting either a duplicated Tlr7 locus (Y-linked auto-
immunity mutation; Yaa) or multiple copies of a Tlr7 transgene 
(Pisitkun et al., 2006; Subramanian et al., 2006; Deane et al., 
2007). It also parallels the autoimmune B cell proliferation 
caused when B cell antigen receptors bind and deliver excessive 
amounts of self-DNA to TLR9 (Leadbetter et al., 2002). Hence 
the findings here provide a rationale for future studies to test for 
inherited or somatic MYD88 mutations in systemic lupus and 
other autoimmune diseases.
The results also indicate that overexpression of wild-type 
MYD88 causes B cell dysregulation. B cells that expressed the 
highest levels of the MYD88WT:EGFP vector were indeed 
stimulated to divide in culture. In contrast, EGFPmid B cells 
expressing the different vectors were only stimulated to di-
vide if the vector encoded MYD88L265P:EGFP. These results 
provide experimental evidence to explain the observation 
that MYD88 overexpression without L265P mutation is seen 
in 36% of DLBCL cases and is associated with tumor recur-
rence and shortened disease-free survival (Choi et al., 2013).
The findings here reveal surprising differences between 
lymphoma MYD88L265P and CARD11 mutations. Both break 
the tuning of intracellular signals from their respective recep-
tors (TLRs, BCRs) that normally prevents proliferative re-
sponses to self. However, based on the findings here TLR 
signaling appears more heavily fortified against this contin-
gency, and has the potential to cross-interfere with normal 
tolerance to BCR self-ligands. MYD88L265P was sufficient 
to initiate B cell proliferation much like activated alleles of 
CARD11, but MYD88L265P differed from CARD11 because 
within 1–2 d, it induced a decrease in NF-B p65 RelA 
phosphorylation, a decrease in down-regulation of NF-B- 
induced cell surface proteins, and an increase in Bim protein. 
Cell division was prematurely terminated by apoptosis between 
3 and 4 d. These self-extinguishing effects of MYD88L265P 
were negated by a Tnfaip3 partial loss of function mutation. 
Tnfaip3 is induced by NF-B signaling as an early response 
gene and encodes the A20 protein, a ubiquitin modifier that 
inhibits formation of linear and K63-linked ubiquitin chains 
on key proteins in the NF-B signaling pathway to provide a 
negative feedback that terminates further activation of NF-B 
(Harhaj and Dixit, 2012; Tokunaga et al., 2012; Verhelst 
et al., 2012). Tnfaip3 inactivation accompanies MYD88L265P 
in 24% of ABC-DLBCL (Ngo et al., 2011) and in 38% of 
Waldenström’s macroglobulinemia (Braggio et al., 2009). The fact 
that many MYD88L265P-bearing lymphomas have not acquired 
an inactivating Tnfaip3 mutation raises the possibility that other 
recurring lymphoma mutations might represent alternative 
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Statistical analysis. All experiments were analyzed using Prism version 5 
(GraphPad). Statistically significant p-values <0.05, <0.01, and <0.001, re-
spectively are indicated and were determined using a two-tailed unpaired 
Student’s t test.
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Flow cytometric analysis was performed as described in (Jeelall et al., 2012). 
For cell division analysis, transduced cells at day 0 were loaded with 20 µM 
CTV (Invitrogen) for 30 min before culture.
Adoptive transfer. Retrovirally transduced B cells were cultured in media 
containing anti-CD40 for 36 h after spin-infection, washed, and then analyzed 
by hemocytometer and flow cytometry as above. 5 × 106 to 10 × 106 cultured 
viable B cells were injected into the lateral tail vein of each recipient mouse.
Western blot. EGFP+ transduced splenic B cells were sorted and analyzed 
by Western blotting as previously described (Jeelall et al., 2012). Myd88 and 
phospho-p65 NF-B primary antibodies obtained from Cell Signaling Tech-
nology were used at 1:1,000 dilutions. Horseradish peroxidase–conjugated 
anti–rabbit IgG secondary antibody purchased from Cell Signaling Technol-
ogy was used at 1:2,500 dilution. Membranes were reprobed with antibody 
to  tubulin obtained from Cell Signaling Technology at 1:5,000 dilution 
as a loading control.
Gene expression analysis. EGFP+ B cells were harvested on day 1 of culture 
without anti-CD40, sorted, and resuspended in TRIzol. Phase separation was 
performed by the addition of chloroform and centrifugation at 12,000 g for 
15 min, followed by isopropanol RNA precipitation. The air-dried RNA pellet 
was dissolved in RNase-free water, and mRNA expression was analyzed on 
Affymetrix mouse ST 1.0 arrays as per the manufacturer’s instructions.
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